1. Home
  2. PGEN vs VISN Comparison

PGEN vs VISN Comparison

Compare PGEN & VISN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$7.70

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Vistance Networks Inc. Common Stock

VISN

Vistance Networks Inc. Common Stock

HOLD

Current Price

$6.48

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
VISN
Founded
1998
1976
Country
United States
United States
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Radio And Television Broadcasting And Communications Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.7B
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
PGEN
VISN
Price
$7.70
$6.48
Analyst Decision
Buy
Hold
Analyst Count
5
1
Target Price
$8.33
$21.00
AVG Volume (30 Days)
3.7M
8.2M
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
641.01
EPS
0.03
24.79
Revenue
$230,981,000.00
$1,931,600,000.00
Revenue This Year
$1,115.92
$9.44
Revenue Next Year
$81.04
$5.91
P/E Ratio
$258.83
$0.26
Revenue Growth
N/A
N/A
52 Week Low
$2.99
$6.00
52 Week High
$8.04
$19.91

Technical Indicators

Market Signals
Indicator
PGEN
VISN
Relative Strength Index (RSI) 64.70 29.91
Support Level $6.57 $6.00
Resistance Level $7.72 $12.59
Average True Range (ATR) 0.27 0.22
MACD 0.05 0.11
Stochastic Oscillator 76.41 56.94

Price Performance

Historical Comparison
PGEN
VISN

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About VISN Vistance Networks Inc. Common Stock

Vistance Networks Inc operates in the communications technology sector, providing solutions designed to support the delivery and management of communications services. It serves customers globally through teams involved in product development, implementation, and customer support. The company designs and develops network infrastructure and connectivity solutions focused on reliability and performance. Its offerings include intelligent networking technologies intended to support evolving communication requirements.

Share on Social Networks: